BIEDX - Radiology Education’s Post

More primary prostate cancer lesions were detected with 64Cu-SAR-bisPSMA PET/CT compared with 68Ga-PSMA-11, and 64Cu-SAR-bisPSMA showed a higher uptake (PROPELLER NCT04839367) and higher detection of lesions 1 day after dosing (COBRA NCT05249127) Note also that 64Cu has a longer half-life than 68Ga (12.7 hours vs <2 hours), and SAR-bisPSMA is bivalent vs the monovalent 68Ga-PSMA-11. Because of those characteristics, 64Cu-SAR-bisPSMA has longer tumor retention, 2-3-fold higher tumor uptake, and greater detection of PC lesions compared to the currently approved PSMA-targeting PET agents.

Do you know the difference between basket and umbrella clinical trial designs? 🤔 This new blog post breaks it down for you! Learn about what they are, how they're coupled with the use of patient-derived xenograft (PDX) mouse models, and why these approaches pave the way for more personalized, targeted cancer therapies. 🎯

A phase 3 trial of the 64Cu-SAR-bisPSMA diagnostic in patients with biochemical recurrence of prostate cancer plans to initiate. This follows FDA guidance and is supported by data from successful COBRA and PROPELLER trials. https://lnkd.in/egB7f-nZ

#CROs are fundamental to the development of cancer treatments but face multiple challenges. In this new blog, Jennifer Duff analyzes the biggest #clinicaltrial trends in oncology this year that are reshaping the role of CROs, and how the Zelta platform is helping CROs to optimize their workflows and simplify trials. https://lnkd.in/eaU9wR3R

How #antibodydrugconjugates aim to take down cancer. Read the article below 👇 https://lnkd.in/eadvP4Eh

Pembrolizumab, Chemoradiotherapy Meet Overall Survival Endpoint for Cervical Cancer: Previously, the study met the other primary endpoint of progression free survival, showing statistically significant and clinically meaningful improvements compared to chemoradiotherapy alone. #finance #pharmacy #lifesciences

The FDA recently approved the first-ever #celltherapy to treat solid tumors! Cell therapy is just getting going, more innovation #bioprocessing needed to get to scale and open access, but great to read at NPR https://n.pr/3Td506e #CellandGeneTherapy #Oncology

FDA Approves First One-time Cell Therapy for a Solid Tumor! Exciting strides in immunotherapy! The FDA's impending approval decision for Iovance Biotherapeutics has the potential to breathe new life into the field, which has been evolving for over four decades. This milestone exemplifies the relentless pursuit of progress in healthcare, where groundbreaking advancements often arise from years of dedicated research and development. If approved, Iovance's treatment could offer a promising new option for patients with certain types of cancer, providing a beacon of hope in the ongoing fight against the disease. This news underscores the profound impact that innovative therapies can have on improving patient outcomes and transforming the landscape of cancer care. #Immunotherapy #HealthcareInnovation #FDAApproval #CancerTreatment https://lnkd.in/eV6CXvPK

"Lifileucel is the first TIL therapy to be approved by the U.S. Food and Drug Administration. And it is the first immune-cell therapy to win FDA approval for treating solid tumors such as melanoma," says Sara Reardon. This is a breakthrough for modern medicine. It will pave the way for TILs to be used to treat other cancers, including lung and pancreatic tumors, in the near future. Looking forward to what lies ahead. #TIL #Tumors #Oncology #Medicine #Healthcare #Cancer

Comprehensive review of RLT history in treating prostate cancer, current use, ESMO 2024 data review with expert commentary. #prostatecancer#radiopharmaceuticals#expertcommentary